Alexandra Gerlach, Associate Editor

Trastuzumab deruxtecan (T-DXd) yielded favorable outcomes and improved survival rates.

In a session at the 2025 Virtual Conference on Pain and Palliative Care, Isabella Zerfas, PharmD, and Abbey Galligan, PharmD, BCPS, explore effective pain management strategies for opioid use disorder (OUD) and complex persistent opioid dependence.

The data were presented at the ESMO Breast Cancer 2025 Annual Meeting.

Studies suggest that prolonged activation of MUC1-C encourages disease progression.

The combination demonstrated improved efficacy compared with ruxolitinib as a monotherapy.

Don Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, received a leadership award at the 2025 HOPA Annual Meeting.

Pharmacists compare real-world practice data with clinical trial results and discuss supportive care options for patients.

The approval expands the therapy’s indication to children as young as 7 years.

Aficamten, a cardiac myosin inhibitor, gains FDA approval, offering hope for improved cardiovascular health in patients with obstructive hypertrophic cardiomyopathy.

New data reveals that combining pertuzumab with trastuzumab significantly improves survival rates in HER2+ breast cancer patients, reducing death risk by 17%.

Combining olaparib with neoadjuvant chemotherapy enhances survival rates for early-stage gBRCAm triple-negative breast cancer, offering new hope for patients.

Ibrutinib offers comparable survival outcomes for high-risk chronic lymphocytic leukemia patients, challenging traditional prognostic markers in real-world settings.

The data are from the phase 2 iMMagine-1 study.

FDA and CDC halt Ixchiq chikungunya vaccine for adults 60 years and older due to severe adverse events, including fatalities, urging caution in vaccination practices.

The executive order gives pharmaceutical companies 30 days to voluntarily lower prices.

Explore the latest insights on emerging antibody drug conjugates for HER2 breast cancer and real-world management strategies.

The study found that only 38% of nations have risk-based pneumococcal vaccine policies.

Lacy La Fever, PharmD, MS, discussed outcomes associated with different carboplatin AUC dosing strategies.

The most substantial reduction was achieved 2 to 3 years after vaccination with a sustained protective effect lasting up to 8 years.

The fixed-dose combination yielded a 49% greater reduction in low density lipoprotein cholesterol (LDL-C) compared with placebo.

The agent demonstrated promising tolerability and manageable safety.

Trastuzumab deruxtecan was safe and efficacious prior to treatment with paclitaxel, trastuzumab, and pertuzumab.

Adherence to GLP-1 receptor agonists showed a 59% drop in inpatient hospital costs.

Patients with myelofibrosis who stopped ruxolitinib on the first day of conditioning did not show higher rates of acute graft-vs-host disease (GVHD).

The agent targets B7-H3, a commonly overexpressed protein in diffuse intrinsic pontine glioma (DIPG).

There was no significant increase in severe adverse events associated with statin use.

One dose of the vaccine compared with 2 may help increase global HPV vaccine uptake.

This installment of our series on ADCs and HER2 breast cancer offers key insights about novel agents in clinical trials and management of ADC therapies.

The salvage therapy led to an 80% overall response rate in patients with relapsed/refractory multiple myeloma.